WO2023022271A1 - 항-igsf1 항체 및 이의 용도 - Google Patents
항-igsf1 항체 및 이의 용도 Download PDFInfo
- Publication number
- WO2023022271A1 WO2023022271A1 PCT/KR2021/011139 KR2021011139W WO2023022271A1 WO 2023022271 A1 WO2023022271 A1 WO 2023022271A1 KR 2021011139 W KR2021011139 W KR 2021011139W WO 2023022271 A1 WO2023022271 A1 WO 2023022271A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igsf1
- cancer
- antibody
- seq
- cells
- Prior art date
Links
- 102100022514 Immunoglobulin superfamily member 1 Human genes 0.000 claims abstract description 173
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 80
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 45
- 201000005202 lung cancer Diseases 0.000 claims abstract description 45
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 101150009156 IGSF1 gene Proteins 0.000 claims abstract description 14
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000012634 fragment Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 33
- 239000013598 vector Substances 0.000 claims description 26
- 108091033319 polynucleotide Proteins 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 24
- 239000002157 polynucleotide Substances 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 239000013604 expression vector Substances 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 206010043515 Throat cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 201000006491 bone marrow cancer Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 201000010175 gallbladder cancer Diseases 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 201000005787 hematologic cancer Diseases 0.000 claims description 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000026037 malignant tumor of neck Diseases 0.000 claims description 3
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 201000006134 tongue cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 210000000436 anus Anatomy 0.000 claims 1
- 201000004962 larynx cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 160
- 230000027455 binding Effects 0.000 abstract description 29
- 230000014509 gene expression Effects 0.000 abstract description 26
- 230000001965 increasing effect Effects 0.000 abstract description 12
- 230000004614 tumor growth Effects 0.000 abstract description 8
- 238000011577 humanized mouse model Methods 0.000 abstract description 6
- 210000002865 immune cell Anatomy 0.000 abstract description 5
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 5
- 230000002093 peripheral effect Effects 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 4
- 238000001764 infiltration Methods 0.000 abstract description 4
- 102000004127 Cytokines Human genes 0.000 abstract description 2
- 108090000695 Cytokines Proteins 0.000 abstract description 2
- 230000028993 immune response Effects 0.000 abstract description 2
- 101710181541 Immunoglobulin superfamily member 1 Proteins 0.000 description 160
- 239000000427 antigen Substances 0.000 description 28
- 102000036639 antigens Human genes 0.000 description 28
- 108091007433 antigens Proteins 0.000 description 28
- 239000000872 buffer Substances 0.000 description 27
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 26
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 23
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 23
- 108010076504 Protein Sorting Signals Proteins 0.000 description 21
- 239000006228 supernatant Substances 0.000 description 21
- 239000000203 mixture Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 108020001507 fusion proteins Proteins 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000011532 immunohistochemical staining Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000037449 immunogenic cell death Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 108040007629 peroxidase activity proteins Proteins 0.000 description 3
- 102000013415 peroxidase activity proteins Human genes 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000010923 batch production Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011426 transformation method Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 1
- 101001073212 Arabidopsis thaliana Peroxidase 33 Proteins 0.000 description 1
- 102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 108700010013 HMGB1 Proteins 0.000 description 1
- 101150021904 HMGB1 gene Proteins 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 102100037907 High mobility group protein B1 Human genes 0.000 description 1
- 101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 101001044371 Homo sapiens Immunoglobulin superfamily member 1 Proteins 0.000 description 1
- 101001123325 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-beta Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 201000001096 IGSF1 deficiency syndrome Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100028961 Peroxisome proliferator-activated receptor gamma coactivator 1-beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 208000028265 X-linked central congenital hypothyroidism with late-onset testicular enlargement Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000029305 central congenital hypothyroidism Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 102000049904 human IGSF1 Human genes 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 230000033885 plasminogen activation Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Definitions
- the present invention relates to a "novel” antibody that specifically binds to "IGSF1" and a “pharmaceutical” composition for "prevention” or “treatment of cancer” containing the same as an active ingredient.
- Chemotherapy methods such as anticancer drugs in the treatment of cancer have been effective to some extent, but many studies are required due to various pathogenesis of cancer and resistance to anticancer drugs. Although the cancer cure rate has improved with the development of diagnosis and treatment technology in recent decades, the 5-year survival rate for many advanced cancers remains at 5 to 50%. In addition, for some cancers, despite various studies and treatments, survival rates for the past 20 years have not changed significantly.
- Korean Publication No. 2016-0014564 discloses that the immunoglobulin superfamily member 1 (IGSF1) gene can be used as a biomarker for predicting sensitivity to mesenchymal-epithelial transition factor (MET) inhibitors.
- IGSF1 immunoglobulin superfamily member 1
- MET mesenchymal-epithelial transition factor
- the present inventors have developed an antibody that specifically binds to the C-terminus of IGSF1 as a result of research to develop an anticancer agent with high therapeutic effect, in particular, a therapeutic agent for effectively treating cancer in which IGSF1 is overexpressed. It was confirmed that the antibody effectively prevents or treats cancer.
- one aspect of the present invention provides an anti-cancer agent comprising an anti-IGSF1 antibody that specifically binds to the C-terminus of IGSF1 as an active ingredient.
- a heavy chain variable region comprising H-CDR1 of SEQ ID NO: 1, H-CDR2 of SEQ ID NO: 2 and H-CDR3 of SEQ ID NO: 3; and L-CDR1 of SEQ ID NO: 4, L-CDR2 of SEQ ID NO: 5, and L-CDR3 of SEQ ID NO: 6, and an antibody or fragment thereof specific to IGSF1 comprising a light chain variable region.
- Another aspect of the present invention provides a polynucleotide encoding the IGSF1-specific antibody or fragment thereof, an expression vector containing the polynucleotide, and a transformed cell into which the expression vector is introduced.
- Another aspect of the present invention culturing the transformed cells; And it provides a method for producing an antibody or fragment thereof specific to IGSF1 comprising recovering the anti-IGSF1 antibody or fragment thereof.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the IGSF1-specific antibody or fragment thereof as an active ingredient.
- Another aspect of the present invention provides a method for preventing or treating cancer comprising administering the IGSF1-specific antibody or fragment thereof to a subject.
- the anti-IGSF1 antibody according to the present invention showed high specificity and high binding ability to IGSF1.
- the anti-IGSF1 antibody according to the present invention increased the infiltration of immune cells into the spheroids when IGSF1-overexpressing lung cancer cell spheroids and human peripheral mononuclear cells were co-cultured.
- the anti-IGSF1 antibody according to the present invention inhibited tumor growth in humanized mice transplanted with IGSF1-overexpressing human lung cancer cells.
- the antibody increased the expression of cytokines in cytotoxic T lymphocytes present in tumor tissues.
- the anti-IGSF1 antibody can inhibit tumor growth by increasing the infiltration and immune response of immune cells into the tumor tissue in which IGSF1 expression is increased. Therefore, the anti-IGSF1 antibody can be used as an anticancer agent that effectively treats cancer in which IGSF1 is overexpressed.
- FIG. 1 is a diagram confirming the expression level of IGSF1 in IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) and a control group (NCI-H292 MOCK) through Western blotting and RT-PCR.
- Figure 2 is co-culture of IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O / E) and control (NCI-H292 MOCK) spheroids and human peripheral mononuclear cells (PBMC), tumor infiltrating lymphocytes (TIL) present in spheroids ) is a confirmed drawing.
- NCI-H292 IGSF1 O / E human lung cancer cells
- NCI-H292 MOCK human peripheral mononuclear cells
- TIL tumor infiltrating lymphocytes
- Figure 3 shows the degree of distribution of hCD45+ cells by flow cytometry to confirm the presence of tumor-infiltrating lymphocytes in the tumor tissues of mice transplanted with IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) or a control group (NCI-H292 MOCK). It is a graph showing the result of analysis through analysis.
- Figure 4 shows the expression of IGSF1 and the presence of tumor-infiltrating lymphocytes in tumor tissues of mice transplanted with IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) or control (NCI-H292 MOCK) immunohistochemical staining (immunohistochemistry) It is a drawing showing the result confirmed by .
- Figure 5 is a graph showing the results of analyzing the binding affinity of the WM-A1-3389 antibody to the IGSF1 antigen using ELISA.
- Figure 6 is a graph showing the results of analyzing the binding affinity of the WM-A1-3389 antibody to the intracellular IGSF1 antigen using FACS analysis.
- Figure 7 is a result of analyzing the binding force of the WM-A1-3389 antibody to IGSF1 expressed in cells in IGSF-overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) and a control group (NCI-H292 MOCK) using FACS analysis. is a graph showing
- Figure 8 shows two types of IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E and HEK293E IGSF1 O/E) and control groups (NCI-H292 MOCK and HEK293E MOCK) treated with shIGSF1 in IGSF1 knockdown (K/D) cell lines. It is a graph showing the results of analyzing the binding specificity of the WM-A1-3389 antibody.
- TIL tumor-infiltrating lymphocytes present in spheroids after treatment with IgG or WM-A1-3389 antibody when IGSF1 overexpressing human lung cancer cell (NCI-H292 IGSF1 O/E) spheroids and human peripheral mononuclear cells (PBMC) are co-cultured (TIL) is a drawing confirmed through a microscope image.
- IGSF1 overexpressing human lung cancer cell NCI-H292 IGSF1 O/E
- PBMC peripheral mononuclear cells
- Figure 10 shows the co-culture of IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) and control (NCI-H292 MOCK) spheroids and human peripheral mononuclear cells (PBMC), after treatment with IgG or WM-A1-3389 antibody. It is a graph showing the expression of HMGB1 and Hsp90 in spheroids.
- 11 is a graph showing the measurement of tumor size in the IgG or WM-A1-3389 antibody-administered group in a mouse model transplanted with IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E).
- FIG. 12 is a graph showing the individual tumor sizes of mice administered with IgG or WM-A1-3389 antibody in a mouse model implanted with IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E).
- FIG. 13 is a view showing the results of analyzing the expression level of IGSF1 in tissues of Caucasian lung cancer patients.
- One aspect of the present invention provides an anti-cancer agent comprising an anti-IGSF1 antibody that specifically binds to the C-terminus of IGSF1 as an active ingredient.
- IGSF1 is a membrane protein encoded by the IGSF1 gene found on the X chromosome of humans and other mammalian species. Although the function of IGSF1 in normal cells is not well known, IGSF1 mutations are known to cause diseases such as IGSF1 deficiency syndrome or central hypothyroidism.
- the IGSF1 may include any mammalian IGSF1 without limitation, but may preferably refer to human IGSF1.
- the IGSF1 protein includes all native or mutant IGSF1 proteins, but is not limited thereto.
- the native IGSF1 protein generally refers to a polypeptide comprising the amino acid sequence of the native IGSF1 protein, and the amino acid sequence of the native IGSF1 protein generally refers to the amino acid sequence found in naturally occurring IGSF1.
- the information on IGSF1 can be obtained from a known database such as GenBank of the National Institutes of Health, and may have, for example, the amino acid sequence of Genebank accession number NP_001164433.1 or the amino acid sequence of SEQ ID NO: 19, but is not limited thereto.
- anti-IGSF1 antibody refers to an antibody capable of binding to IGSF1, and may be used interchangeably with “IGSF1-specific antibody” in the present invention.
- the anti-IGSF1 antibody can specifically bind to the C-terminus of IGSF1.
- the form of the antibody may include both whole antibodies and antibody fragments.
- anti-cancer agent may include any composition or drug that exhibits a preventive or therapeutic effect on cancer.
- the anti-IGSF1 antibody binding to the C-terminus of IGSF1 can effectively kill cancer in which IGSF1 is overexpressed.
- the cancer is gastric cancer, liver cancer, lung cancer, non-small cell lung cancer, colorectal cancer, bladder cancer, bone cancer, blood cancer, breast cancer, melanoma, thyroid cancer, parathyroid cancer, bone marrow cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, tongue cancer , skin cancer, sinus tumor, cervical cancer, head or neck cancer, gallbladder cancer, oral cancer, perianal cancer, colon cancer, and central nervous system tumors.
- a heavy chain variable region comprising H-CDR1 of SEQ ID NO: 1, H-CDR2 of SEQ ID NO: 2 and H-CDR3 of SEQ ID NO: 3; and L-CDR1 of SEQ ID NO: 4, L-CDR2 of SEQ ID NO: 5, and L-CDR3 of SEQ ID NO: 6, and an antibody or fragment thereof specific to IGSF1 comprising a light chain variable region.
- the term "antibody” refers to an immunoglobulin molecule that reacts immunologically with a specific antigen, and refers to a protein molecule that specifically recognizes an antigen.
- the antibody may be whole antibody, monoclonal antibody, polyclonal antibody, single domain antibody, single chain antibody, multispecific antibody, human antibody, humanized antibody, chimeric antibody, intrabody, scFv, Fab fragment, F (ab') fragments, Fvs linked by disulfide bonds (sdFv), and epitope binding fragments of any of the above.
- the heavy chain and light chain of immunoglobulin may include a constant region and a variable region, respectively.
- Light chain and heavy chain variable regions of immunoglobulin include three variable regions called complementarity determining regions (CDRs) and four framework regions (FRs).
- the CDR mainly serves to bind to an epitope of an antigen.
- the CDRs of each chain are typically called CDR1, CDR2, CDR3 sequentially starting from the N-terminus, and are identified by the chain on which the particular CDR is located.
- Antibodies and fragments thereof specific to IGSF1 of the present invention may include a heavy chain variable region (VH) including H-CDR1 of SEQ ID NO: 1, H-CDR2 of SEQ ID NO: 2, and H-CDR3 of SEQ ID NO: 3.
- the IGSF1-specific antibody and fragment thereof of the present invention may include a light chain variable region (VL) comprising L-CDR1 of SEQ ID NO: 4, L-CDR2 of SEQ ID NO: 5, and L-CDR3 of SEQ ID NO: 6 there is.
- VL light chain variable region
- the heavy chain variable region may have an amino acid sequence of SEQ ID NO: 7
- the light chain variable region may have an amino acid sequence of SEQ ID NO: 8.
- the antibody may be referred to as WM-A1-3389.
- the heavy chain variable region of the antibody is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% of the amino acid sequence of SEQ ID NO: 7, It may comprise or consist of an amino acid sequence that has about 99%, or about 100% identity.
- the light chain variable region of the antibody is about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98% of the amino acid sequence of SEQ ID NO: 8 It may comprise or consist of an amino acid sequence that has %, about 99% or about 100% identity.
- Immunoglobulin heavy chain constant regions exhibit different amino acid composition and order and therefore possess different types of antigenicity.
- immunoglobulins can be classified into five categories and referred to as immunoglobulin isotypes: IgM, IgD, IgG, IgA and IgE.
- Corresponding heavy chains are ⁇ chain, ⁇ chain, ⁇ chain, ⁇ chain and ⁇ chain, respectively.
- Igs of the same type can be classified into different subtypes. For example, IgG can be classified as IgG1, IgG2, IgG3 and IgG4.
- Light chains can be classified as ⁇ or ⁇ chains according to the different constant regions.
- Each of the five types of IgG can have ⁇ or ⁇ chains.
- the IGSF1-specific antibody of the present invention may include a constant region derived from IgG, IgA, IgD, IgE, or IgM, or a partial hybrid thereof.
- hybrid means that sequences corresponding to immunoglobulin heavy chain constant regions of two or more different origins exist within a single chain immunoglobulin heavy chain constant region. For example, a hybrid of one to four domains selected from the group consisting of CH1, CH2 and CH3 of IgG, IgA, IgD, IgE and IgM is possible.
- the IGSF1-specific antibody of the present invention includes a light chain constant region (LC)
- the light chain constant region may be derived from a ⁇ or ⁇ light chain.
- antibody fragment refers to a scFv fragment, which is an Fv fragment that binds to IGSF1, as well as a Fab fragment, Fab' fragment, F(ab')2 fragment having antigen-binding activity, and refers to the scFv fragment of the present invention. It includes the CDR regions of the antibodies described in.
- An Fv fragment is the smallest antibody fragment that contains a heavy chain variable region and a light chain variable region, without a constant region, and retains all antigen-binding sites.
- Another aspect of the present invention provides a polynucleotide encoding an antibody or fragment thereof specific for IGSF1.
- the anti-IGSF1 antibodies and fragments thereof are as described above.
- the heavy chain region of the polynucleotide may include the nucleotide sequence of SEQ ID NO: 9, and the light chain region may include the nucleotide sequence of SEQ ID NO: 10.
- one or more bases may be mutated by substitution, deletion, insertion, or a combination thereof.
- a synthesis method well known in the art for example, the method described in the literature (Engels and Uhlmann, Angew Chem IntEd Engl., 37:73-127, 1988) can be used. and triester, phosphite, phosphoramidite and H-phosphate methods, PCR and other auto-primer methods, oligonucleotide synthesis methods on solid supports, and the like.
- the polynucleotide is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87% of each nucleotide sequence of SEQ ID NO: 9 or SEQ ID NO: 10 %, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97% %, at least about 98%, at least about 99% or at least about 100% identity.
- the polynucleotide may additionally include a signal sequence or a leader sequence.
- signal sequence refers to a nucleic acid encoding a signal peptide that directs the secretion of a target protein.
- the signal peptide is cleaved after translation in the host cell.
- the signal sequence of the present invention is a nucleotide encoding an amino acid sequence that initiates movement of a protein through an endoplasmic reticulum (ER) membrane.
- ER endoplasmic reticulum
- the signal sequence is well known in the art and usually includes 16 to 30 amino acid residues, but may include more or less amino acid residues.
- a typical signal peptide consists of three domains: a basic N-terminal domain, a central hydrophobic domain, and a more polar C-terminal domain.
- the central hydrophobic region contains 4 to 12 hydrophobic residues that anchor the signal sequence throughout the membrane lipid bilayer during migration of the immature polypeptide.
- the signal sequence is cleaved within the lumen of the ER by cellular enzymes commonly known as signal peptidases.
- the signal sequence may be tPa (tissue plasminogen activation), HSV gDs (signal sequence of herpes simplex virus glycoprotein D), IgG signal sequence, or growth hormone secretion signal sequence.
- secretion signal sequences used in higher eukaryotic cells including mammals and the like can be used.
- Signal sequences useful in the present invention include antibody light chain signal sequences, such as antibody 14.18 (Gillies et al., J. Immunol. Meth 1989. 125:191-202), antibody heavy chain signal sequences, such as MOPC141 antibody heavy chain signals. sequence (Sakano et al., Nature, 1980. 286: 676-683) and other signal sequences known in the art (see, eg, Watson et al., Nucleic Acid Research, 1984. 12:5145-5164). .
- Another aspect of the present invention provides a vector comprising a polynucleotide encoding the IGSF1-specific antibody or fragment thereof.
- the heavy chain region of the polynucleotide may include the nucleotide sequence of SEQ ID NO: 9, and the light chain region may include the nucleotide sequence of SEQ ID NO: 10.
- the polynucleotide may additionally include a signal sequence or a leader sequence.
- the IGSF1-specific antibody and its fragments and signal sequences are as described above.
- the vector may be two vectors each including the polynucleotides of the heavy chain and the light chain, or a bicistronic vector including both the polynucleotides.
- a “vector” is capable of being introduced into a host cell and then recombination and integration into the host cell genome.
- the vector is understood to be a nucleic acid means comprising a nucleotide sequence capable of autonomous replication as an episome.
- Such vectors include linear nucleic acids, plasmids, phagemids, cosmids, RNA vectors, viral vectors, minichromosomes, and analogues thereof.
- viral vectors include, but are not limited to, retroviruses, adenoviruses, and adeno-associated viruses.
- the vector may be plasmid DNA, phage DNA, etc., commercially developed plasmids (pUC18, pBAD, pIDTSAMRT-AMP, etc.), Escherichia coli-derived plasmids (pYG601BR322, pBR325, pUC118, pUC119, etc.), Bacillus subtilis plasmids derived from spp.
- pUB110, pTP5, etc. yeast-derived plasmids (YEp13, YEp24, YCp50, etc.), phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, ⁇ gt10, ⁇ gt11, ⁇ ZAP, etc.), animal viral vectors (retrovirus ), adenovirus, vaccinia virus, etc.), insect virus vectors (baculovirus, etc.), and the like. Since the expression level and modification of the protein of the vector appear differently depending on the host cell, it is preferable to select and use the host cell most suitable for the purpose.
- the plasmid may contain a selectable marker such as an antibiotic resistance gene, and host cells containing the plasmid may be cultured under selective conditions.
- the term "gene expression” or “expression” of a protein of interest is understood to mean transcription of DNA sequences, translation of mRNA transcripts and secretion of fusion protein products or fragments thereof.
- a useful expression vector can be RcCMV (Invitrogen, Carlsbad) or variants thereof.
- the expression vector may include a human cytomegalovirus (CMV) promoter for promoting continuous transcription of a target gene in mammalian cells and a bovine growth hormone polyadenylation signal sequence for increasing the steady-state level of RNA after transcription.
- CMV human cytomegalovirus
- bovine growth hormone polyadenylation signal sequence for increasing the steady-state level of RNA after transcription.
- Another aspect of the present invention provides a transformed cell into which an expression vector containing a polynucleotide encoding the IGSF1-specific antibody or fragment thereof is introduced.
- Antibodies and fragments thereof specific to IGSF1 are as described above.
- transformed cell refers to prokaryotic and eukaryotic cells into which a recombinant expression vector may be introduced.
- the transformed cell may be prepared by introducing a vector into a host cell and transforming the cell.
- the fusion protein of the present invention can be produced by expressing the polynucleotide contained in the vector.
- the transformation may be performed by various methods. As long as the fusion protein of the present invention can be produced, it is not particularly limited thereto. Specifically, the transformation method is a CaCl 2 precipitation method, and a CaCl 2 precipitation method using a reducing material called DMSO (dimethyl sulfoxide) Hanahan method, electroporation, calcium phosphate precipitation, protoplast fusion, agitation using silicon carbide fibers, agrobacteria mediated transformation, transformation using PEG, dextran sulfate, lipofectamine and drying / Suppression mediated transformation methods and the like can be used.
- a target may be delivered into a cell using virus particles as a means of infection.
- vectors can be introduced into host cells by gene bombardment or the like.
- the host cell used for preparing the transformed cell can also produce the fusion protein of the present invention, it is not particularly limited thereto.
- the host cell may include, but is not limited to, cells of prokaryotic, eukaryotic, mammalian, plant, insect, fungal or cellular origin.
- prokaryotic cell Escherichia coli may be used.
- yeast may be used as an example of a eukaryotic cell.
- the mammalian cells include CHO cells, F2N cells, COS cells, BHK cells, Bowes melanoma cells, HeLa cells, 911 cells, AT1080 cells, A549 cells, SP2/0 cells, human lymphoblastoid ), NSO cells, HT-1080 cells, PERC.6 cells, HEK293 cells or HEK293T cells, etc. may be used, but are not limited thereto, and any cell that can be used as a mammalian host cell known to those skilled in the art can be used.
- glycosylation-related genes possessed by host cells are manipulated through a method known to those skilled in the art to sugar chains of fusion proteins.
- the pattern eg sialic acid, fucosylation, glycosylation
- the pattern can be tailored.
- Another aspect of the present invention provides a method for producing the IGSF1-specific antibody or fragment thereof.
- IGSF1-specific antibodies and fragments thereof are as described above.
- the method for producing the fusion protein includes i) culturing the transformed cell; and ii) recovering the anti-IGSF1 antibody or fragment thereof of the present invention.
- cultivation refers to a method of growing microorganisms under appropriately artificially controlled environmental conditions.
- the method of culturing the transformed cells may be performed using a method widely known in the art.
- the culture is not particularly limited thereto as long as it can be produced by expressing the fusion protein of the present invention.
- the culture may be cultured continuously in a batch process or fed batch or repeated fed batch process.
- the step of recovering the fusion protein dimer from the culture may be performed by a method known in the art.
- the recovery method is not particularly limited thereto as long as the produced fusion protein of the present invention can be recovered.
- the recovery method is centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (eg ammonium sulfate precipitation), chromatography (eg ion exchange, affinity, hydrophobicity, and size exclusion).
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer comprising the IGSF1 antibody or fragment thereof as an active ingredient.
- the cancer may be a cancer in which IGSF1 is overexpressed.
- the cancer is gastric cancer, liver cancer, lung cancer, non-small cell lung cancer, colorectal cancer, bladder cancer, bone cancer, blood cancer, breast cancer, melanoma, thyroid cancer, parathyroid cancer, bone marrow cancer, rectal cancer, throat cancer, laryngeal cancer, esophageal cancer, pancreatic cancer, tongue cancer , It may be any one selected from the group consisting of skin cancer, sinus tumor, uterine cancer, head or neck cancer, gallbladder cancer, oral cancer, perianal cancer, colon cancer, and central nervous system tumor.
- prevention refers to all activities of suppressing or delaying the onset of cancer by administration of the pharmaceutical composition.
- treatment refers to all activities that improve or beneficially change symptoms of cancer by administration of the pharmaceutical composition.
- the anti-IGSF1 antibody or fragment thereof can exhibit anticancer activity, it may be included in any amount (effective amount) depending on the purpose of use, formulation, and combination.
- effective amount refers to the amount of an active ingredient capable of inducing an anticancer effect. Such an effective amount can be determined empirically within the ordinary skill of the skilled artisan.
- the pharmaceutical composition of the present invention contains the antibody as an active ingredient in an amount of about 0.1% to about 90% by weight, specifically about 0.5% to about 75% by weight, more specifically about 1% to about 1% by weight based on the total weight of the composition. It may contain 50% by weight.
- the pharmaceutical composition of the present invention may include a conventional non-toxic pharmaceutically acceptable carrier formulated into a formulation according to a conventional method.
- the pharmaceutically acceptable carrier may be any carrier as long as it is a non-toxic material suitable for delivery to a patient. Distilled water, alcohol, fats, waxes and inert solids may be included as carriers. Pharmaceutically acceptable adjuvants (buffers, dispersants) may also be included in the pharmaceutical composition.
- the term "pharmaceutically acceptable carrier” refers to a carrier or diluent that does not stimulate organisms and does not inhibit the biological activity and properties of the administered compound.
- Acceptable pharmaceutical carriers for compositions formulated as liquid solutions are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as sweeteners, solubilizers, wetting agents, emulsifiers, isotonic agents, absorbents, antioxidants, preservatives, lubricants, fillers, buffers, and bacteriostatic agents may be added as necessary. can do.
- compositions of the present invention can be prepared in a variety of dosage forms for parenteral administration (eg, intramuscular, intravenous or subcutaneous injection).
- parenteral administration eg, intramuscular, intravenous or subcutaneous injection.
- the pharmaceutical composition of the present invention may be formulated in the form of an injection, transdermal administration, nasal inhalation, and suppository along with a suitable carrier according to a method known in the art.
- injectable formulations include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried formulations and suppositories.
- Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions.
- Witepsol, Macrogol, Tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used as a base for the suppository.
- conventional additives such as solubilizers, tonicity agents, suspending agents, emulsifiers, stabilizers, and preservatives may be included in the injection.
- An antibody or composition of the present invention can be administered to a patient in a therapeutically effective amount or a pharmaceutically effective amount.
- the term "administration” means introducing a predetermined substance into a subject by an appropriate method, and the administration route of the composition may be administered through any general route as long as it can reach the target tissue.
- Intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, topical administration, intranasal administration, intrarectal administration may be administered, but is not limited thereto.
- terapéuticaally effective amount or “pharmaceutically effective amount” is an amount of an antibody or composition effective for preventing or treating a target disease, sufficient to treat the disease with a reasonable benefit / risk ratio applicable to medical treatment It means an amount that does not cause side effects.
- the level of the effective amount is the patient's state of health, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and excretion rate, duration of treatment, factors including drugs used in combination or concurrently, and It may be determined according to other factors well known in the medical field.
- the effective amount of the antibody in the composition of the present invention may vary depending on the age, sex, and weight of the patient, and is generally about 0.1 mg to about 1,000 mg, or about 5 mg to about 200 mg per kg of body weight per day or It can be administered every other day or divided into 1 to 3 times a day. However, since it may increase or decrease depending on the route of administration, severity of disease, sex, weight, age, etc., the scope of the present invention is not limited thereto.
- the term "individual” refers to a subject to which the composition of the present invention can be applied (prescribed), and may be mammals such as rats, mice, livestock, and the like, including humans. Preferably, it may be a human, but is not limited thereto.
- the antibody of the present invention or a pharmaceutical composition containing the same may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered single or multiple times.
- the other therapeutic agent may further include any compound or natural extract known to have anticancer activity and whose safety has already been verified to increase or enhance anticancer activity.
- Another aspect of the present invention provides the use of an antibody or fragment thereof specific to IGSF1 for preparing a drug for preventing or treating cancer.
- Anti-IGSF1 antibodies and fragments thereof, cancer, prevention and treatment herein are the same as described above.
- Another aspect of the present invention provides the use of an antibody or fragment thereof specific for IGSF1 for preventing and treating cancer.
- Anti-IGSF1 antibodies and fragments thereof, cancer, prevention and treatment herein are the same as described above.
- Another aspect of the present invention provides a method for preventing and treating cancer comprising administering an antibody or fragment thereof specific to IGSF1 to a subject.
- the anti-IGSF1 antibody and fragment thereof, cancer, administration, treatment and prevention are the same as described above.
- the subject may be a mammal, preferably a human.
- the subject may be a cancer patient or an individual who is highly likely to suffer from cancer.
- the administration route, dosage and frequency of administration of the IGSF1-specific antibody or fragment thereof may be administered to the subject in various ways and amounts depending on the condition of the patient and the presence or absence of side effects, and the optimal administration method, dosage and frequency of administration can be selected in an appropriate range by a person skilled in the art.
- the IGSF1-specific antibody or fragment thereof may be administered in combination with other drugs or biochemically active substances known to have therapeutic effects on cancer, or formulated in combination with other drugs.
- IGSF1 protein expression vector After amplifying only the extracellular domain of IGSF1 through PCR from the Jurkat cell cDNA library, using the N293F vector (Yi Biologics Co., Ltd.), human Fc (fragment crystallizable region) and Histag ( his-tag) was fused to construct an IGSF1 protein expression vector.
- HEK293F cells were transfected with the constructed IGSF1 expression vector, and cultured for 6 days in a medium supplemented with 1 mM Valporic acid (valproate).
- first purification of the IGSF1 extracellular domain using protein A agarose second purification of the IGSF1 extracellular domain using Superdex 200 gel filtration chromatography, It was used for antibody selection.
- bio-panning is performed using the prepared human antibody library phage (Y Bio Logics Co., Ltd.) to specifically bind to the antigen Only phages were eluted. Second and third rounds of biopanning were performed with the phages amplified in the first round of biopanning. ELISA was performed to confirm the antigen specificity of the positive phage antibody pool obtained through each round of biopanning. In addition, it was confirmed that the anti-IGSF1 antibody was enriched in the phage pool obtained through the third round.
- the specificity of IGSF1 and other antigens was comparatively analyzed through ELISA method.
- the antibodies obtained in this way were converted from phage to whole IgG vectors, and it was confirmed that the heavy and light chain sequences of the 95 converted clones matched those of the phage antibodies.
- the most optimized antibody was selected and named "WM-A1-3389".
- the CDR sequences of the WM-A1-3389 antibody are shown in Table 1 below.
- the polynucleotide (SEQ ID NO: 23) encoding the heavy chain (SEQ ID NO: 21) was loaded into the N293F vector (Y BioLogics Co., Ltd.) (hereafter, HC DNA).
- the polynucleotide (SEQ ID NO: 24) encoding the light chain (SEQ ID NO: 22) was loaded into the N293F vector (Y BioLogics Co., Ltd.) (hereinafter referred to as LC DNA).
- the WM-A1-3389 antibody was obtained and purified. The purified protein was confirmed by SDS-PAGE.
- IGSF1 was overexpressed in NCI-H292, a human lung cancer cell line, or HEK293E, a human embryonic kidney cell line, to construct an IGSF1 overexpressed cell line (FIG. 1).
- MOCK is a control group without IGSF1 expression.
- an expression vector (OriGene Technologies, Inc., Cat No.RC209621) containing a polynucleotide encoding IGSF1 was transfected into human lung cancer cell line NCI-H292 cells or human embryonic kidney cell line HEK293F cells. Thereafter, transfected cells were selected by culturing in a medium containing G418 (neomycin). The IGSF1 expression level was checked for the selected clones, and the clone showing the highest IGSF1 expression was selected and used in the experiment.
- MOCK means an empty vector not loaded with a polynucleotide encoding IGSF1.
- Example 2.2 Analysis of the relationship between IGSF1 expression and tumor-infiltrating lymphocytes in lung cancer cell line spheroids
- tumor-infiltrating lymphocytes TIL
- TIL tumor-infiltrating lymphocytes
- NCI-H292 IGSF1 O/E cells and NCI-H292 MOCK cells were each 2 ⁇ 10 4 cells/well in a U-Bottom 96-well plate (Nunc, 174925 ) and incubated for 72 hours in a 37 ° C carbon dioxide incubator.
- Peripheral blood mononuclear cells (PBMC) were prepared by centrifugation at 1,200 rpm for 10 minutes, removing the supernatant, and resuspending in PBS.
- the formed spheroids were transferred to an ultra-low-attachment 96-well plate (Corning, CLS3474) by 2 wells, and then seeded with CFSE-stained peripheral blood mononuclear cells at 1 ⁇ 10 5 cells/well and incubated at 37° C. in a carbon dioxide incubator for 24 co-cultured for a period of time.
- Tumor-infiltrating lymphocytes TIL
- NCI-H292 MOCK cells were used as a control for IGSF1 overexpressing cells.
- TIL tumor infiltrating lymphocytes
- Example 2.3 Analysis of the relationship between IGSF1 expression and tumor-infiltrating lymphocytes in tumor tissues of humanized mice transplanted with lung cancer cell lines
- tumor-infiltrating lymphocytes were identified in tumor tissues of humanized mice transplanted with IGSF1-overexpressing human lung cancer cells.
- NSG mice SID (NSGA) mice, F transplanted with human peripheral blood mononuclear cells (PBMC) were treated with NCI-H292 IGSF1 O/E cells, a human lung cancer cell line overexpressing IGSF1, or NCI-H292 MOCK cells as a control group. Tumor parts of the mice were collected on the 17th day after transplantation at 5 ⁇ 10 6 cells per mouse.
- Human peripheral blood mononuclear cells were isolated from the collected tumors and subjected to FACS analysis, and tumor-infiltrating lymphocytes and IGSF1 expression levels in the tumor tissue were confirmed through immunohistochemical staining of the tumor tissue.
- the tumor tissue was first treated with collagenase B (Roche, cat. #11088815001) and reacted at 37° C. for 2 hours or more to decompose the tumor tissue. When the tumor tissue was completely disintegrated into cells, it was separated into single cells by pipetting with a 1 ml pipette.
- the isolated single cells were transferred to a 50 ml tube (SPL, cat. #50050) and washed with 20 ml of PBS. Then, centrifugation was performed at 1,200 rpm for 3 minutes and the supernatant was removed. The remaining cells were reacted with DNase I (Roche, cat. #11284932001) at 37°C for 20 minutes. Thereafter, 20 ml of PBS was added, and the supernatant was removed by centrifugation at 1,200 rpm for 3 minutes. Remaining cells were treated with 0.25% Trysin/EDTA (GIBCO, cat. #15400-054). After mixing the cells well, a cell strainer (SPL, cat.
- IGSF1 tumor lymphocytes expressed in the tumor and the expression of IGSF1 were confirmed by immunohistochemical staining.
- human lung cancer cell line NCI-H292 IGSF1 O/E cells or NCI-H292 MOCK cells were injected into NSG mice (SID (NSGA) mice, F) transplanted with human peripheral blood mononuclear cells (PBMC), 5 ⁇ 10 per mouse. 6 cells were transplanted. After that, on day 17, sections of tumor tissue collected from mice were deparaffinized and rehydrated.
- Target retrieval buffer for heat-induced epitope retrieval, it was immersed in target retrieval buffer and heated in a microwave oven for 15 minutes. Then, after being placed in target retrieval buffer for 30 minutes, washed three times with Tris-buffered saline-0.05% Tween 20 (TBS-T), and blocked for 60 minutes with a blocking solution.
- Anti-IGSF1 antibody (Santacruz, sc-393786) as primary antibody was diluted 1:100 and allowed to bind overnight at 4°C.
- hCD45+ cells which are human immune cells, decreased in the tumor tissues of humanized mice transplanted with IGSF1 overexpressing human lung cancer cells (NCI-H292 IGSF1 O/E) (FIG. 4 ).
- the binding affinity of the WM-A1-3389 antibody to the IGSF1 antigen was confirmed at the in vitro level using ELISA analysis.
- PBST 4% skim milk
- WM-A1-3389 antibody was serially diluted in 4% skim milk (PBST) at 1/3 concentration to 12 concentrations, and then reacted at room temperature for 2 hours.
- PBST 4% skim milk
- the wells were washed with PBST, treated with human IgG Fc-HRP antibody, and allowed to react at room temperature for 1 hour.
- TMB peroxidase substrate was added to check the degree of color development, and the absorbance was measured at 450 nm, and the results were compared and analyzed.
- the Kd value of the WM-A1-3389 antibody was 2.2 ⁇ 10 -11 , indicating high binding affinity to the IGSF1 antigen (FIG. 5).
- IGSF1 overexpressing human lung cancer cells NCI-H292 IGSF1 O/E
- NCI-H292 MOCK NCI-H292 MOCK
- the media of NCI-H292 IGSF1 O/E cells and NCI-H292 MOCK cells were removed, washed once with PBS, and treated with 2 ml of 0.25% trypsin-EDTA to separate the cells.
- the separated cells were diluted with 8 ml of PBS (hereinafter referred to as FACS buffer) containing 2% FBS and 0.05% sodium azide, and then centrifuged at 1,200 rpm for 1 minute to remove the supernatant. Then, the cells were resuspended in FACS buffer to a concentration of 1 ⁇ 10 5 cells/ml. Thereafter, the supernatant was removed by dispensing 1 ml each into a FACS tube and centrifuging at 1,200 rpm for 1 minute.
- the pellet remaining in the FACS tube was released by vortexing, and the WM-A1-3389 antibody was diluted by 1/4 from 20 ⁇ M to 0 ⁇ M per 200 ⁇ l of FACS buffer to a total of 12 concentrations. , and reacted at 4° C. for 30 minutes. After the reaction was completed, 1 ml of FACS buffer was added to each tube, and the supernatant was removed by centrifugation at 1,200 rpm for 1 minute. This process was carried out a total of two times.
- the pellet remaining in the FACS tube was released by vortexing, and FITC-labeled goat anti-human IgG antibody (Invitrogen, 62-8411) was added at 5 ⁇ g/ml per 200 ⁇ l of FACS buffer and incubated at 4° C. for 30 minutes. reacted After completion of the reaction, 1 ml of FACS buffer was added to each tube, and the supernatant was removed by centrifugation at 1,200 rpm for 1 minute. This process was performed twice in total.
- the remaining pellet was resuspended in 200 ⁇ l of FACS buffer and subjected to FACS analysis.
- FACS analysis the FITC fluorescence value labeled on each cell was measured using a BD LSRFortessa TM Flow Cytometer, and the results were analyzed using FlowJo software, and the EC50 value was calculated using a sigma plot program.
- NCI-H292 MOCK cells were used as a control for IGSF1 overexpressing cells.
- the medium of IGSF1 overexpressed human lung cancer cells (NCI-H292 IGSF1 O/E) and its control (NCI-H292 MOCK) was removed, washed once with PBS, and 2 ml of 0.25% trypsin-EDTA.
- Cells were separated by treatment.
- the separated cells were diluted with 8 ml of PBS (hereinafter referred to as FACS buffer) containing 2% FBS and 0.05% sodium azide, and then centrifuged at 1,200 rpm for 1 minute to remove the supernatant.
- the cells were resuspended in FACS buffer to a concentration of 1 ⁇ 10 5 cells/ml. Thereafter, the supernatant was removed by dispensing 1 ml each into a FACS tube and centrifuging at 1,200 rpm for 1 minute.
- the pellet remaining in the FACS tube was released by vortexing, and 0.4 ⁇ g of human IgG isotype antibody (Bio X cell, BE0297) or WM-A1-3389 antibody per 200 ⁇ l of FACS buffer was added and reacted at 4° C. for 30 minutes. After completion of the reaction, 1 ml of FACS buffer was added to each tube, and the supernatant was removed by centrifugation at 1,200 rpm for 1 minute. This process was performed a total of two times.
- the cell pellet remaining in the FACS tube was released by vortexing, and 0.4 ⁇ g of FITC-labeled goat anti-human IgG antibody (Invitrogen, 62-8411) per 200 ⁇ l of FACS buffer was added and reacted for 30 minutes at 4° C. made it
- the WM-A1-3389 antibody-treated group showed 2.6% binding ability in the control group (NCI-H292 MOCK) and 78.9% binding force in the IGSF1 overexpressing cells (NCI-H292 IGSF1 O/E). binding was shown (FIG. 7).
- IGSF1 overexpressed NCI-H292 IGSF1 O / E cells and HEK293E IGSF1 O / E cells were transfected with shRNA (hereinafter, shIGSF1) that specifically binds to mRNA encoding IGSF1 to reduce the expression of IGSF1 (
- shIGSF1 K/D cells the binding ability of the WM-A1-3389 antibody to the intracellular IGSF1 antigen was measured.
- a control for transfection IGSF1 K / D
- scramble RNA without shIGSF1 hereinafter referred to as sc cells
- a human IgG isotype was used as a control for the WM-A1-3389 antibody.
- the binding ability in IGSF1 K/D cells was compared with the binding ability in sc cells.
- NCI-H292 MOCK cells and HEK293E MOCK cells were used as controls for IGSF1 overexpressing cells, respectively.
- NCI-H292 IGSF1 O/E and MOCK
- HEK293E IGSF1 O/E and MOCK
- Example 5 Analysis of immunocancer efficacy of anti-IGSF1 antibodies in lung cancer cell spheroids
- lung cancer cell spheroids and peripheral blood mononuclear cells were co-cultured to confirm tumor infiltrating lymphocytes (TIL) and immunogenic cell death.
- the co-cultured cells and the supernatant were collected in a tube and centrifuged at 1,200 rpm for 2 minutes to remove the supernatant.
- the cell pellet was treated with 500 ⁇ l of 0.25% trypsin-EDTA to form single cells, diluted with 2 ml of PBS (hereafter referred to as FACS buffer) containing 2% FBS and 0.05% NaN 3 , and centrifuged at 1,200 rpm for 3 minutes. It was separated and the supernatant was removed.
- PBS hereafter referred to as FACS buffer
- TIL tumor infiltrating lymphocytes
- ICD immunogenic cell death
- IGSF1-overexpressing human lung cancer cells NCI-H292 IGSF1 O/E were transplanted into peripheral blood mononuclear cell humanized model (PBMC humanized model) mice. Afterwards, the tumor growth inhibitory effect of the WM-A1-3389 antibody was evaluated.
- 6-week-old female peripheral blood mononuclear cell humanized mice (Gem biosciences) were purchased and purified for 1 week, and then IGSF1-overexpressing human lung cancer cells NCI-H292 IGSF1 O/E (5 ⁇ 10 6 cells/mouse) were mixed with PBS. It was diluted in Matrigel and injected subcutaneously (200 ⁇ l) into the right ventral side of the mouse. When the size of the tumor reached about 120 mm 3 , IgG isotype (control) or WM-A1-3389 antibody was intraperitoneally administered at a dose of 10 mg/kg, respectively. Administration was performed once every 3 days for 4 weeks, and the tumor size and body weight of mice were measured twice a week.
- FACS analysis was performed by collecting blood and tumors from satellite group mice. After the administration was completed, the experimental animals were euthanized, and the tumors were removed and weighed. A human IgG isotype was used as a control for the WM-A1-3389 antibody.
- the WM-A1-3389 antibody-administered group showed higher tumor growth inhibition efficacy than the control group, and showed a tumor inhibition rate (TGI) of about 64.5% (FIG. 11).
- TGI tumor inhibition rate
- Example 7 Analysis of IGSF1 expression in tissues of lung cancer patients of Caucasian ethnicity
- IGSF1 The expression of IGSF1 in tissues of Caucasian lung cancer patients was confirmed by immunohistochemical staining.
- target recovery buffer for heat-induced epitope recovery, followed by heating in a microwave oven for 15 minutes did After that, the target recovery buffer was further reacted for 30 minutes. Then, after washing three times with Tris buffered saline 0.05% Tween 20 (TBS-T), blocking was performed for 60 minutes with a blocking solution.
- Anti-IGSF1 antibody (Santacruz, sc-393786) as primary antibody was diluted 1:100 and allowed to bind overnight at 4°C.
- tissue sections were washed 3 times with TBS-T and reacted with endogenous peroxidase blocking reagent (Cell Marque, 925B) for 5 minutes. And, the secondary antibodies (Vector, PK-6101 PK-6102) were bound for 60 minutes at room temperature. Thereafter, washed three times with TBS-T, treated with avidin-biotin, and reacted for 60 minutes, followed by DAB staining (Vector, SK-4100). Stained tissue sections were observed under a microscope (FIG. 13).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
Abstract
Description
WM-A1-3389 | ||
CDR | 아미노산 서열 | 서열번호 |
H-CDR1 | GGTFSTYA | 1 |
H-CDR2 | IIPFVGTV | 2 |
H-CDR3 | VRDGGRSYFDS | 3 |
L-CDR1 | TSNIGSNL | 4 |
L-CDR2 | DNH | 5 |
L-CDR3 | VAWDDSLNGYV | 6 |
아미노산 서열 | 서열번호 | |
중쇄 (heavy chain) |
QVQLVQSGAEVKRPGSSVKVSCKASGGTFSTYAISWVRQAPGQGLEWMGRIIPFVGTVDYAQKFQDRVTITADKSTNTAYMELSSLRSEDTAVYYCVRDGGRSYFDSWGPGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK | 21 |
경쇄 (light chain) |
QFVLTQPPSVSAAPGQDVIISCSGNTSNIGSNLVSWFQQFPETAPKLLIYDNHKRPSGISDRFSGTKSGTSASLAISGLQSEDEADYYCVAWDDSLNGYVFGTGTKVTVLRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC | 22 |
Claims (12)
- IGSF1의 C 말단에 특이적으로 결합하는 항-IGSF1 항체를 유효성분으로 포함하는 항암제.
- 서열번호 1의 H-CDR1, 서열번호 2의 H-CDR2 및 서열번호 3의 H-CDR3을 포함하는 중쇄 가변영역; 및서열번호 4의 L-CDR1, 서열번호 5의 L-CDR2 및 서열번호 6의 L-CDR3을 포함하는 경쇄 가변영역을 포함하는 것인, IGSF1에 특이적인 항체 또는 이의 단편.
- 제2항에 있어서,상기 중쇄 가변영역은 서열번호 7의 아미노산 서열을 가지며;상기 경쇄 가변영역은 서열번호 8의 아미노산 서열을 가지는 것인, IGSF1에 특이적인 항체 또는 이의 단편.
- 서열번호 1의 H-CDR1, 서열번호 2의 H-CDR2 및 서열번호 3의 H-CDR3을 포함하는 중쇄 가변영역을 암호화하는 폴리뉴클레오티드.
- 서열번호 4의 L-CDR1, 서열번호 5의 L-CDR2 및 서열번호 6의 L-CDR3을 포함하는 경쇄 가변영역을 암호화하는 폴리뉴클레오티드.
- 제4항 및 제5항의 폴리뉴클레오티드를 포함하는 발현 벡터.
- 제6항의 벡터가 도입된 형질전환 세포.
- i) 제7항의 형질전환 세포를 배양하는 단계; 및ii) IGSF1에 특이적인 항체 또는 이의 단편을 회수하는 단계를 포함하는 IGSF1에 특이적인 항체 또는 이의 단편의 생산방법.
- 제2항 또는 제3항의 IGSF1에 특이적인 항체 또는 이의 단편을 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물.
- 제9항에 있어서,상기 암은 IGSF1이 과발현된 것을 특징으로 하는, 암 예방 또는 치료용 약학 조성물.
- 제10항에 있어서,상기 암은 위암, 간암, 폐암, 비소세포 폐암, 대장암, 방광암, 골암, 혈액암, 유방암, 흑색종양, 갑상선암, 부갑상선암, 골수암, 직장암, 인후암, 후두암, 식도암, 췌장암, 설암, 피부암, 뇌종양, 자궁암, 두부 또는 경부암, 담낭암, 구강암, 항문 부근암, 결장암 및 중추신경계 종양으로 구성된 군으로부터 선택되는 어느 하나인 것인, 암 예방 또는 치료용 약학 조성물.
- 제2항 또는 제3항의 IGSF1에 특이적인 항체 또는 이의 단편을 개체에 투여하는 단계를 포함하는 암 예방 또는 치료 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3177927A CA3177927A1 (en) | 2021-08-20 | 2021-08-20 | Anti-igsf1 antibody and use thereof |
CN202180048750.4A CN116635418A (zh) | 2021-08-20 | 2021-08-20 | 抗igsf1抗体及其用途 |
AU2021437023A AU2021437023A1 (en) | 2021-08-20 | 2021-08-20 | Anti-IGSF1 antibody and use thereof |
BR112022021592A BR112022021592A2 (pt) | 2021-08-20 | 2021-08-20 | Anticorpo anti-igsf1 e uso do mesmo |
PCT/KR2021/011139 WO2023022271A1 (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
KR1020237005825A KR20240046103A (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2021/011139 WO2023022271A1 (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023022271A1 true WO2023022271A1 (ko) | 2023-02-23 |
Family
ID=85223221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/011139 WO2023022271A1 (ko) | 2021-08-20 | 2021-08-20 | 항-igsf1 항체 및 이의 용도 |
Country Status (6)
Country | Link |
---|---|
KR (1) | KR20240046103A (ko) |
CN (1) | CN116635418A (ko) |
AU (1) | AU2021437023A1 (ko) |
BR (1) | BR112022021592A2 (ko) |
CA (1) | CA3177927A1 (ko) |
WO (1) | WO2023022271A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024090916A1 (ko) * | 2022-10-24 | 2024-05-02 | 웰마커바이오 주식회사 | 항-igsf1 항체를 포함하는 암 치료용 약학 조성물 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053243A1 (en) * | 2005-02-27 | 2009-02-26 | Institute For Antibodies Co., Ltd | Anti-IgSF4 Antibody and Utilization of the Same |
KR20160014564A (ko) | 2014-07-29 | 2016-02-11 | 재단법인 아산사회복지재단 | Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도 |
-
2021
- 2021-08-20 CA CA3177927A patent/CA3177927A1/en active Pending
- 2021-08-20 CN CN202180048750.4A patent/CN116635418A/zh active Pending
- 2021-08-20 KR KR1020237005825A patent/KR20240046103A/ko unknown
- 2021-08-20 AU AU2021437023A patent/AU2021437023A1/en active Pending
- 2021-08-20 WO PCT/KR2021/011139 patent/WO2023022271A1/ko active Application Filing
- 2021-08-20 BR BR112022021592A patent/BR112022021592A2/pt unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090053243A1 (en) * | 2005-02-27 | 2009-02-26 | Institute For Antibodies Co., Ltd | Anti-IgSF4 Antibody and Utilization of the Same |
KR20160014564A (ko) | 2014-07-29 | 2016-02-11 | 재단법인 아산사회복지재단 | Met 저해제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도 |
Non-Patent Citations (7)
Title |
---|
BERNARD DANIEL J, BRÛLÉ EMILIE, SMITH COURTNEY L, JOUSTRA SJOERD D, WIT JAN M: "From Consternation to Revelation: Discovery of a Role for IGSF1 in Pituitary Control of Thyroid Function", JOURNAL OF THE ENDOCRINE SOCIETY, vol. 2, no. 3, 1 March 2018 (2018-03-01), US , pages 220 - 231, XP093036316, ISSN: 2472-1972, DOI: 10.1210/js.2017-00478 * |
ENGELSUHLMANN, ANGEW CHEM INTED ENGL., vol. 37, 1988, pages 73 - 127 |
GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1989, pages 191 - 202 |
SAKANO ET AL., NATURE, vol. 286, 1980, pages 676 - 683 |
WANG YING, BRÛLÉ EMILIE, SILANDER TANYA, BAK BEATA, JOUSTRA SJOERD D., BERNARD DANIEL J.: "The short mRNA isoform of the immunoglobulin superfamily, member 1 gene encodes an intracellular glycoprotein", PLOS ONE, vol. 12, no. 7, 7 July 2017 (2017-07-07), pages e0180731 - e0180731-11, XP093036318, DOI: 10.1371/journal.pone.0180731 * |
WATSON ET AL., NUCLEIC ACID RESEARCH, vol. 12, 1984, pages 5145 - 5164 |
YAOYAO GUAN; YINGHAO WANG; ADHEESH BHANDARI; ERJIE XIA; OUCHEN WANG: "IGSF1: A novel oncogene regulates the thyroid cancer progression", CELL BIOCHEMISTRY AND FUNCTION, vol. 37, no. 7, 25 July 2019 (2019-07-25), GB , pages 516 - 524, XP071523442, ISSN: 0263-6484, DOI: 10.1002/cbf.3426 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024090916A1 (ko) * | 2022-10-24 | 2024-05-02 | 웰마커바이오 주식회사 | 항-igsf1 항체를 포함하는 암 치료용 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CA3177927A1 (en) | 2023-02-20 |
BR112022021592A2 (pt) | 2023-03-14 |
KR20240046103A (ko) | 2024-04-08 |
AU2021437023A1 (en) | 2023-03-09 |
CN116635418A (zh) | 2023-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2718323B1 (en) | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING BETA-KLOTHO AND AN FGFR1c | |
JP7361610B2 (ja) | 抗pd-l1抗体及びその使用 | |
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
KR101683884B1 (ko) | 항-EpCAM 항체 및 이의 용도 | |
KR100909290B1 (ko) | 항암 항체 | |
WO2021201571A1 (ko) | Igsf1 에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법 | |
WO2021256724A1 (ko) | Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도 | |
KR20210142638A (ko) | Cd3 항원 결합 단편 및 이의 응용 | |
TW202115123A (zh) | 一種抗pd-l1抗原結合蛋白及其應用 | |
WO2023022271A1 (ko) | 항-igsf1 항체 및 이의 용도 | |
CN114369161B (zh) | Mica抗体及其应用 | |
KR20180016320A (ko) | 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도 | |
JP2024502758A (ja) | Cd73結合タンパク質及びその使用 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2019216675A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2022231032A1 (ko) | 항-cntn4 특이적 항체 및 그의 용도 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
WO2023211068A1 (ko) | 항-igsf1 항체 및 항-pd-1 항체를 포함하는 암 치료용 약학 조성물 | |
WO2022025585A1 (ko) | 항-lilrb1 항체 및 그의 용도 | |
WO2023229303A1 (ko) | Igsf1의 c-말단에 결합하는 항체 및 이의 용도 | |
EP4161962A1 (en) | Human anti-grp94 antibodies and uses | |
WO2023277627A1 (ko) | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 | |
WO2022124764A1 (ko) | Cd47에 특이적인 항체 및 이의 용도 | |
WO2023090780A1 (ko) | 자연살해세포-특이적 키메릭항원수용체 및 이의 용도 | |
WO2022250450A1 (ko) | 항 메소텔린 scFv를 포함하는 키메릭 항원 수용체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 3177927 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180048750.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 17997019 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022021592 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021437023 Country of ref document: AU Date of ref document: 20210820 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112022021592 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221024 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21930594 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021930594 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021930594 Country of ref document: EP Effective date: 20240320 |